Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

ABSTRACT:

Background

Biomarkers can improve clinical trial efficiency, but designing and interpreting biomarker-driven trials require knowledge of relationships among biomarkers, clinical covariates, and endpoints. We investigated these relationships across genomic subgroups of glioblastoma (GBM) within our institution (DF/BWCC), validated results in The Cancer Genome Atlas (TCGA), and demonstrated potential impacts on clinical trial design and interpretation.

Methods

We identified genotyped patients at DF/BWCC, and clinical associations across 4 common GBM genomic biomarker groups were compared along with overall survival (OS), progression-free survival (PFS), and survival post-progression (SPP). Significant associations were validated in TCGA. Biomarker-based clinical trials were si

SUBMITTER: Tanguturi SK 

PROVIDER: S-EPMC5570228 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature